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Key messages
Recent research on antiplatelet therapy has advanced the knowledge of
early, intensive treatment for recurrent stroke in minor ischaemic stroke
or transient ischaemic attack
In patients with high risk, non-disabling ischaemic cerebrovascular events,
including minor stroke and transient ischaemic attack, short term dual
antiplatelet therapy should be given within 24 hours after the onset of
symptoms and as early as possible
Further studies are needed to evaluate antiplatelet strategies, explore
whether dual antiplatelet therapy could benefit broader patient population,
and improve adherence of the recommended antiplatelet therapy
The risk of recurrent stroke and other vascular events is high in
the first few weeks after index minor ischaemic stroke and high
risk transient ischaemic attack (5-11.7%).1 2 Dual antiplatelet
therapy (DAPT), comprising clopidogrel and aspirin, is an
effective strategy for reducing recurrence.1 An expert panel from
the MAGIC group (http://magicproject.org/) recently produced
a strong rapid recommendation in The BMJ for starting DAPT
within 24 hours of symptom onset and continuing for 10-21
days in patients with minor stroke or transient ischaemic attack.3
The evidence for this came from a systematic review and
meta-analysis of published clinical trials.4 Most current
international guidelines,5-8 but not all,9 recommend early (within
24 hours) and short term (a duration of 21 days or 21-30 days)
DAPT in patients with minor stroke or transient ischaemic attack
(table 1).
Questions remain regarding choice of antiplatelet strategy,
possibility of safe expansion of DAPT to a broader patient
population, and adherence of patients to recommended
antiplatelet therapy in clinical practice.
Recent trials
In the past five years, trials on acute antiplatelet treatment have
focused on evaluating the efficacy and safety of more intensive
treatment to prevent recurrent stroke after minor ischaemic
stroke or high risk transient ischaemic attack. These include
dual therapy versus monotherapy,1 2 triple versus dual antiplatelet
treatment,10 and a potentially more potent agent (ticagrelor)
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compared with aspirin alone (table 2).11-13 The findings of these
studies have greatly advanced the antiplatelet strategy for
secondary prevention of stroke in patients with minor ischaemic
stroke or transient ischaemic attack.
Treatment population for DAPT
Patients who have a minor stroke or a transient ischaemic attack
are at high risk of developing thrombosis and having ischaemic
brain damage that could increase their risk of bleeding.1 2 14 More
intensive antiplatelet therapy could be effective and safe in these
patients. The CHANCE and POINT trials compared the efficacy
and safety of DAPT with clopidogrel plus aspirin against aspirin
alone in patients with minor stroke (National Institutes of Health
Stroke Scale (NIHSS) ≤3) or high risk transient ischaemic attack
(ABCD2 score ≥4). The primary results from CHANCE1 and
secondary analysis from POINT15 show that up to 21 days of
dual antiplatelet therapy were both effective and safe (table 2),
indicating that patients with minor stroke or high risk transient
ischaemic attack are suitable for dual antiplatelet therapy with
clopidogrel plus aspirin.
Time window of starting antiplatelet therapy
Approximately 75-80% of recurrent strokes occur in the first
two weeks after onset of the index stroke or transient ischaemic
attack.1 2 Almost all guidelines recommend that antiplatelet
therapy be given as soon as possible after the diagnosis of an
ischaemic event. Five of the recent trials included patients that
started treatment within 24 hours (table 2).1 2 11-13 Exploratory
analysis of the TARDIS trial showed that intensive triple
antiplatelet therapy could significantly reduce recurrence after
mild stroke or transient ischaemic attack, or minor stroke alone,
if started within 24 hours, but not if started after 24 hours (PM
Bath, personal communication). This further supports the
consensus that antiplatelet therapy should be given as soon as
possible within 24 hours.
Duration of dual antiplatelet therapy
Risk of bleeding is the main harm of intensive dual or triple
antiplatelet therapy. The CHANCE and POINT trials showed
similar efficacy of DAPT with up to ~30% reduction of recurrent
stroke (table 2), but the POINT trial also showed a 2.3-fold
increase in the risk of major haemorrhage in the DAPT group
compared with aspirin alone (P=0.02), whereas the CHANCE
trial did not (P=0.73).1 2 This discrepancy is not completely
understood, but a longer duration of DAPT (90 days in the
POINT trial versus 21 days in the CHANCE trial) may be the
explanation.16 A secondary time course analysis of the POINT
trial provided further supportive evidence for the recent rapid
recommendation.3 15 But more systematic studies are needed to
determine how to choose the duration of DAPT more
precisely—between 10 and 21 days in clinical practice.
Future research
Although DAPT with clopidogrel and aspirin is an effective
strategy for secondary stroke prevention, some patients fail to
respond. DAPT is not effective in patients with lacunar strokes,17
but is potent in patients with multiple acute infarctions or
ipsilateral atherosclerotic stenosis.18 19 Further studies are needed
to thoroughly examine the effects of antiplatelet treatment on
minor stroke or transient ischaemic attack with different causes
and to identify those who will respond well.
Pharmacogenetics may also play an important role. A few
genetic polymorphisms have been identified that might influence
the metabolism of clopidogrel, which is a pro-drug that requires
biotransformation to become an active metabolite and exert its
effect.20 Carriers of the CYP2C19 loss of function alleles are
less likely to benefit from clopidogrel.20 Although not
recommended in current clinical practice, genetic testing may
be considered to personalise antiplatelet therapy, especially in
Asian populations, which have high prevalence of the CYP2C19
loss of function allele. Escalation of clopidogrel dosages or
considering new antiplatelet agents (such as ticagrelor) could
be alternatives for those carriers with CYP2C19 loss of function
alleles. The efficacy, feasibility, and cost effectiveness of
treatment for patients with minor stroke or transient ischaemic
attack based on genetic testing requires further evaluation
through randomised controlled trials.
The CHANCE trial and secondary data of POINT have shown
that short term usage of dual antiplatelet therapy further reduced
up to ~30% of recurrent stroke without increased major bleeding
compared with aspirin alone. Clinicians and researchers are
eager to know whether dual antiplatelet therapy can benefit a
broader population of patients who are at high risk of new stroke.
The SOCRATES trial implied that the patient population at
slightly more severe risk (NIHSS ≤5) also benefited from
ticagrelor compared with aspirin in reducing recurrent stroke
as the secondary efficacy outcome (table 2).11 A recent
meta-analysis indicated that DAPT was associated with reduced
stroke recurrence among patients with acute non-cardioembolic
ischaemic stroke or TIA when started within three days of ictus.21
DAPT might also be effective with acceptable safety in broader
patient populations, such as those with more severe stroke
(NIHSS 4-5) or in an expanded time window (within 72 hours
of symptom onset). These matters need further evaluation in
randomised controlled trials.
Whether a treatment is effective will eventually be influenced
by patients’ adherence. Although short term DAPT was shown
to be safe in patients with minor stroke or high risk transient
ischaemic attack, concerns still exist for bleeding risk in clinical
practice. Secondary analysis of the CHANCE trial showed that
DAPT may increase the risk of non-intracranial haemorrhage
in patients with minor strokes.22 Mild bleeding, such as skin
bruises and gum bleeding, could influence physicians’ decisions
and patients’ adherence to antiplatelet therapy. Further research
is needed to improve adherence.
In summary, DAPT should be started as soon as possible within
24 hours of minor ischaemic stroke or high risk transient
ischaemic attack and should be continued up to 21 days. The
21st day is the possible trade-off point to balance treatment
effect and bleeding risk. Further studies are needed to evaluate
novel and more precise antiplatelet therapy after minor
ischaemic stroke and transient ischaemic attack.
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Tables
Table 1| Current recommendations on antiplatelet therapy for patients with minor stroke or TIA
RecommendationsAntiplatelet to be usedGuideline
In patients presenting with minor stroke, treatment for 21 days with dual antiplatelet therapy
(aspirin and clopidogrel) begun within 24 hours can be beneficial for early secondary stroke
prevention for a period of up to 90 days from symptom onset. (Class IIa recommendation,
evidence level B, based on randomised data)
Aspirin plus clopidogrelAHA/ASA, 20185
In very high risk TIA patients (ABCD2 score ≥4) or minor stroke (NIHSS 0-3), a combination
of clopidogrel and aspirin should be given for 21-30 days followed by antiplatelet monotherapy
(such as aspirin or clopidogrel alone). (Evidence level A)
Aspirin plus clopidogrelCanadian Stroke Best Practice
Guideline, 20186
For high risk patients with minor ischaemic stroke or TIA, aspirin plus clopidogrel may be used
in the short term (first three weeks) to prevent stroke recurrence.
The combination of aspirin plus clopidogrel should not be used for the long term secondary
prevention of cerebrovascular disease in people who do not have acute coronary disease or
recent coronary stent
Aspirin plus clopidogrelAustralian Clinical Guidelines for
Stroke Management, 20177
Patients with non-disabling stroke or TIA should receive clopidogrel 300 mg loading dose
followed by 75 mg daily.
The combination of aspirin and clopidogrel is not recommended unless there is another
indication—eg, acute coronary syndrome, recent coronary stent
ClopidogrelRoyal college of Physicians
guideline 20169
Using a combination of aspirin and clopidogrel for 21 days is recommended to patients with
minor stroke (NIHSS 0-3) or high risk TIA (ABCD2 ≥4) within 24 h of onset (Grade I
recommendation, class-A evidence). After 21 days, either aspirin or clopidogrel can be continued
for long term use (Grade I recommendation, class-A evidence)
Aspirin
Clopidogrel
Aspirin plus clopidogrel
Chinese Guidelines 20148
In patients with high risk TIA and minor ischaemic stroke, we recommend starting dual
antiplatelet therapy using aspirin and clopidogrel within 24 hours of the index event (strong
recommendation).
In patients with high risk TIA and minor ischaemic stroke, we recommend giving dual antiplatelet
therapy for 10-21 days after the index event rather than continuing for longer than 21 days
(strong recommendation)
Aspirin plus clopidogrelBMJ Rapid Recommendation3
AHA/ASA=American Heart Association/American Stroke Association. TIA=transient ischaemic attack.
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Table 2| Recent trials in antiplatelet therapy for stroke
THALES13PRINCE12SOCRATES11TARDIS10POINT2CHANCE1
OngoingRecently completed2016201820182013Published year
Randomised,
double blind,
placebo
controlled
Randomised, open label,
blinded endpoint
randomised, double blind,
parallel group
Randomised, open
label, blinded endpoint
Randomised,
double blind,
placebo controlled
Randomised,
double blind,
placebo controlled
Study design
Estimated 13 00067513 199309648815170Sample size
Study
population:
Multiethnic100% Asian29.6% Asian
66.6% white
1.8% black
2% other
2% Asian
94.9% white
2.0% black
1.1% other
3% Asian
75% white
20.4% black
1.5% other
100% Asian  Ethnicity
High risk TIA†,
ipsilateral large
vessel stenosis
≥50%, or minor
stroke (NIHSS
≤5)
TIA*: 16.4%;
Minor stroke‡: 83.6%
TIA* or ipsilateral large vessel
stenosis:26.8%
Minor stroke (NIHSS ≤5):73.2%
TIA* or crescendo TIA:
27%
Ischaemic stroke: 72%
TIA*: 43.2%
Minor stroke‡:
56.8%
TIA*: 27.9%
Minor stroke‡:
72.1%
  Patients
≤24 h≤24 h≤24 h≤48 h≤12 h≤24 hTime from onset
to
randomisation
Interventions:
Day 1: 300 mg
Days 2-30: 75 mg
Day 1: 600 mg
Days 2-90: 75 mg
Day 1: 300 mg
Days 2-90: 75mg
  Clopidogrel
Day 1: 300-325
mg
Days 2-30:
75-100 mg
Days 1-21: 100 mgDay 1: 300 mg
Days 2-30: 75 mg
Days 1-90: 50-325
mg
Day 1: 75-300 mg
Days 2-21: 75 mg
  Aspirin
Days 1-30: either 200
mg twice daily or 150
mg three times a day
  Dipyridamol
Day 1-30: 180
mg
Day 1-90: 180 mgDay 1: 180 mg
Days 2-90: 180 mg
  Ticagrelor
Aspirin:
Day 1: 300-325
mg
Days 2-30:
75-100 mg
Clopidogrel:
Day 1: 300 mg
Days 2-90: 75 mg
Aspirin:
Days 1-21: 100 mg/day;
Aspirin:
Day 1: 300 mg
Days 2-90: 100 mg
Guideline antiplatelet
therapy (aspirin +
dipyridamol, or
clopidogrel alone)
Aspirin:
Days 1-90: 50-325
mg
Aspirin:
Day 1: 75-300 mg
Days 2-21: 75 mg
Controls:
Day 30Day 90Day 90Day 90Day 90Day 90Time of
outcome
Stroke + deathHigh platelet reactivity:
12.5% v 29.7%;
OR:0.34 (0.22 to 0.52),
P<0.001
Stroke + MI + death:
6.7% v 7.5%;
HR: 0.89 (0.78 to 1.01), P=0.07
Ordinal stroke/TIA:
7% v 6%;
cOR: 0.90 (0.67 to
1.20), P=0.47
Stroke + MI + CV
death:
5% v 6.5%
HR: 0.75 (0.59 to
0.95), P=0.02
Stroke:
8.2% v 11.7%
HR: 0.68 (0.57 to
0.81), P<0.001
Primary efficacy
outcome
(intervention v
control)
StrokeStroke:
6.3% v 8.8%
HR:0.70 (0.40 to 1.22), P=0.20
Stroke:
5.9% v 6.8%
HR: 0.86 (0.75
to 0.99), P=0.03
Stroke:
4% v 4%
HR: 1.05 (0.73 to
1.51), P=0.79
Stroke:
4.8% v 6.4%
HR: 0.74 (0.58 to
0.94), P=0.01
Stroke + M I +CV
death:
8.4% v 11.9%
HR: 0.69 (0.58 to
0.82), P<0.001
Secondary
efficacy
outcome
BleedingMajor or minor bleeding:
4.8% v 3.5%;
HR:1.36 (0.64 to 2.88), P=0.42
Major bleeding:
0.5% v 0.6%
HR: 0.83 (0.52
to 1.34), P=0.45
Ordinal bleeding:
20% v 9%
cOR: 2.45 (2.05 to
3.16), P<0.001
Major
haemorrhage:
0.9% v 0.4%
HR: 2.32 (1.10 to
4.87), P=0.02
Moderate to severe
bleeding:
0.4% v 0.3%
HR: 0.84 (0.30 to
2.31), P=0.73
Primary safety
outcome
* ABCD2 score ≥4. †ABCD2 score ≥6. ‡NIHSS ≤3. MI=myocardial infarction. HR=hazard ratio. cOR=common odds ratio. TIA=transient ischaemic attack. NIHSS=National
Institutes of Health Stroke Scale.
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